Skip to main content

Table 1 Tumor characteristics and treatment outcomes

From: Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy options

Patient Age (Sex) Tumor size (cm) TNM stage Tumor histology ARMS-PCR Tumor puritya Treatment Disease outcomec (months)
P1 50 (F) 1.8 × 2.0 1.6 × 1.7 cT3N2M1b IVa AD MAD E19 del NT 55% 51% Gefitinib + RT Progressive (8) Progressive (8)
P2 70 (M) 2.3 × 1.7 3.3 × 2.5 cT4N0M1b IVa AD MAD E19 del NT 31% 20% Gefitinib + RT Stable (18) Stable (18)
P3 54 (M) 2.3 × 1.7 3.0 × 2.0 cT1N2M1b IVa AD MAD E19 del NT 50% 45% Gefitinib + RT Stable (10) Progressive (10)
P4 54 (F) 3.4 × 3.0 5.3 × 3.1 cT2N3M1b IVb AD MAD E19 del NT 37% 35% Gefitinib + RT Progressive (14) Progressive (14)
P5 73 (F) 2.6 × 1.7 4.3 × 2.8 cT2N0M1c IVb AD MAD E19 del NT 52% 52% Gefitinib + RT Progressive (18) Stable (18)
P6 67 (M) 4.4 × 2.8 2.5 × 1.8 cT2N2M1b IVa AD MAD E19 del NT 26% 32% Gefitinib + RT Stable (5) Stable (5)
P7 64 (F) 2.7 × 2.1 2.1 × 1.8 cT2N2M1b IVa P-NSCC MAD L858R NT 24% 37% Gefitinib Deceased (7) Deceased (7)
P8 54 (F) 2.8 × 2.4 1.5 × 0.9 cT1N1M1b IVa AD MAD L858R NT 31% 34% Gefitinib + CT + RT Progressive (3) Stable (3)
P9 61 (F) 3.2 × 2.8 2.5 × 2.4 cT2N3M1c IVb AD MAD L858R NT 60% 57% Erlotinib + CT Progressive (7) Stable (7)
P10 50 (M) 1.7 × 0.6 1.9 × 1.7 cT1bN0M1c IVb AD MAD L858R 24% 25% Osimertinib Stable (4) Stable (4)
P11 66 (M) 1.5 × 1.3 2.6 × 1.3 cT1bN2M1c IVb AD MAD L858R 94% 30% Gefitinib Progressive (17) Stable (17)
P12 49 (M) 2.6 × 1.5 3.6 × 1.1 cT3N0M1c IVb AD MAD G719Xb NT 47% 51% Osimertinib + RT Progressive (12) Stable (12))
P13 59 (M) 5.6 × 6.3 1.2 × 1.4 cT3N0M1c IVb AD MAD L861Q NT 67% 79% Gefitinib Deceased (14) Deceased (14)
P14 52 (M) 2.0 × 1.7 2.5 × 2.7 cT1N2M1b IVa AD MAD EML4-ALK NT 70% 33% Crizotinib + RT Stable (13) Stable (13)
P15 63 (M) 3.4 × 3.7 7.4 × 7.9 cT2N2M1c IVb AD MAD NT 47% 49% CT Progressive (5) Progressive (5)
P16 53 (F) 4.2 × 7.4 2.1 × 2.3 cT4N0M1a IVb AD MAD NT 35% 35% CT + RT Stable (3) Stable (3)
P17 53 (M) 3.2 × 1.9 4.4 × 1.8 cT2N2M1b IVa AD MAD NT 33% 74% CT + RT Deceased (2) Deceased (2)
  1. aTumor purity was defined as the ratio of tumor to normal cells. bARMS-PCR cannot determine the precise amino acid change (X). AD Adenocarcinoma, P-NSCC Poorly differentiated non-small cell carcinoma, MAD Metastatic adenocarcinoma, NT Not tested, CT Chemotherapy, RT Radiotherapy cProgressive disease, defined as > 20% increase in tumor size. Stable disease, defined as either no change or < 20% change in tumor size